Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 UPDATED RISK DISCLOSURE - CUMBERLAND PHARMACEUTICALS INC | updatedriskfactors.htm |
| EX-99.1 - EXHIBIT 99.1 - PRESS RELEASE - ACETADOTE UPDATE - CUMBERLAND PHARMACEUTICALS INC | pressrelease-acetadoteupda.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | February 3, 2017 (January 30, 2017) |
Cumberland Pharmaceuticals Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Tennessee | 001-33637 | 62-1765329 | |||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||
2525 West End Avenue, Suite 950, Nashville, Tennessee | 37203 | ||||
(Address of principal executive offices) | (Zip Code) | ||||
Registrant's telephone number, including area code: (615) 255-0068 | |||||
Not Applicable
____________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On January 30, 2017, the Company issued a press release announcing the Appeals Court ruling in favor of Cumberland in a patent case associated with its Acetadote product. A copy of the press release is furnished as Exhibit 99.1 as well as the Company's updated risk disclosure related to Acetadote at Exhibit 99.2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cumberland Pharmaceuticals Inc. | |
February 3, 2017 | By: Michael Bonner |
Name: Michael Bonner | |
Title: Chief Financial Officer | |